65,437 trials
Pelvic Fractures · Acetabular Fractures · Hip Fractures
Primary: Number of Participants With Wound Infections — 5; 2 participants
Maternal Substance Use · Child Abuse and Neglect
Primary: Maternal Capacity for Reflective Functioning (Assessed With the Parent Development Interview) — 3.59; 3.08; 3.54; 3.47 units on a scale
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Postoperative Nausea and Vomiting
Primary: Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1 — 5.97; 4.76; 6.16; 6.01 hr*ug/ml
Pneumonia · Respiratory Insufficiency
Primary: to Evaluate the Efficacy of CPAP (Group A) in Comparison With Oxygen Therapy With Venturi Mask (Group B, Standard Therapy) in Terms of Achievement of Criteria for…
Accelerated Phase Chronic Myelogenous Leukemia · Blastic Phase Chronic Myelogenous Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission
Primary: Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28. — 20; 8 participants
Meningococcal Meningitis
Primary: Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With HPV and MenACWY-CRM…
Hypertension
Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) — -4.2; -2.4; -3.1; -0.2 mm Hg…
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
Chronic Hepatitis B
Primary: Percentage of Participants With a Virologic Response at Week 48 - Treated Population — 76.1 percentage of participants
Asthma
Primary: Participants With Unscheduled Asthma-related Visits — 29; 26 participants
AIDS · HIV Infections
Primary: Number of Participants With New or Recurrent AIDS Event, or Death — 83; 82 participants — p=0.69
Mid-facial Volume Deficit Related to Aging
Primary: Responder Rate Based on Improvement in Score on Validated 6-point Mid-Face Volume Deficit Scale (MFVDS) — 85.6; 38.9 percentage of responders
Critical Illness
Primary: Hospital Mortality Rate — 11; 13 participants
Myopia
Primary: Papillary Conjunctivitis — 0.98; 0.47 units on a scale